Ricerc@Sapienza

Among mediators of inflammation, chemokines play a pivotal role in the neuroinflammatory process related to Alzheimer's disease (AD). The chemokine Bv8/prokineticin 2 (PROK2) is a critical player in inflammatory and neuroinflammatory diseases and has been demonstrated to be involved in A beta toxicity. The aim of the present study was to extend the research to rats chronically intracerebroventricularly (i.c.v.) injected with A beta, to an AD transgenic mouse model, and subsequently to AD patients, mainly with the aim of detecting a potential biomarker.

Once first Alzheimer's disease (AD) disease-modifying therapies will become available, global healthcare systems will be challenged by a large-scale demand for clinical and biological screening. Validation and qualification of globally accessible, minimally-invasive, and time-, cost-saving blood-based biomarkers needs to be advanced.